Patent strategy for combination drugs and adjunctive agents corresponding to generics.
S10827
What should I do if one of the generics has a remaining patent in the case of a combination of generics?
Lecturer Mr. Akihiko Okuno, Patent Attorney, Representative Employee of SKIP (SK Patent Firm) (Lecturer at the Graduate School of Innovation Management, Tokyo Institute of Technology) Target Audience: Engineers and personnel related to patents Venue: Kawasaki City Educational and Cultural Center, 4th Floor, Room 1 [Kanagawa, Kawasaki] 13 minutes on foot from Kawasaki Station (JR Line, Keikyu Line) Date and Time: August 31, 2011 (Wednesday) 13:00-16:00 Capacity: 30 people *Please apply early as there may be a rush of applications. Participation Fee: [Early Bird Discount Price] 46,200 yen (tax included, including text costs) for up to 2 people from one company *Limited to Tech-Zone members who apply by August 17. Membership registration is free. *After August 17, the [Regular Price] will be 49,350 yen (tax included, including text costs) for up to 2 people from one company. ◆ When applying for the early bird discount, please select “1 person (early discount)” or “2 people (early discount)” in the number registration. ◆ Point discounts from the early bird discount price do not apply. Point discount services can only be applied when applying at the regular price. ◆ If 3 people apply from the same company, the fee will be 69,300 yen.
Inquire About This Product
basic information
In this seminar, we will have a presentation on patent strategies for LCM using combination drugs and adjunctive agents to respond to generics.
Price range
P2
Delivery Time
P2
Applications/Examples of results
1. Patent strategies for LCM using formulations and combination drugs to respond to generics 1-1 Intellectual property strategies of pharmaceutical companies 1-2 "Combination drugs" that combine two or more pharmaceuticals have traditionally been subject to patent protection in Japan, the U.S., and Europe 1-3 New types of combinations in advanced medical fields 1-4 Inventions that have been clarified as newly patentable due to revisions in examination standards 2. Litigation strategies using patent rights for formulations and combination drugs to respond to generics 2-1 Infringement lawsuits Patent lawsuit regarding the combination of Actos and α-glucosidase inhibitors, Part 1 2-2 Lawsuits for cancellation of examination decisions Patent lawsuit regarding the combination of Actos and α-glucosidase inhibitors, Part 2 2-3 Direct infringement and indirect infringement 3. Ideal universal drafting capable of responding to Japan, the U.S., Europe, China, and India 4. How to write strong patent specifications and claims for pharmaceuticals
Company information
Our company has developed its business from "seminar planning" to various forms such as "lecturer dispatch," "publishing planning," "technical consultant dispatch," "trend research," "business matching," and "business development consulting," in order to support clients in a wide range of fields including chemistry, electronics, automotive, energy, medical devices, food, and building materials. By doing so, we have advanced our company and opened up new markets. AndTech promises to continue listening to our clients' voices, entering the business areas and markets they desire, and to remain a company that is loved by our clients, as we share their challenges, think together, and forge new paths.
![[Technology and Achievements] Formulated Products](https://image.mono.ipros.com/public/product/image/3ae/2000707002/IPROS56037727687214461582.png?w=280&h=280)
